A urethral bulking agent for the treatment of female stress urinary incontinence*
Bulkamid is a non-particulate homogenous hydrogel which consists of 97.5% water and 2.5% polyacrylamide.
*due to intrinsic sphincter deficiency in adult women who have SUI
or stress predominant mixed incontinence.
What makes

different?
How Bulkamid works
Non-particulate permanent homogenous gel.
How other bulking agents work
Particulate combination gels, where micro particles are suspended in a transient carrier liquid.
A graph showing reported success rates of women treated with Bulkamid and Contigen at 12 months4
77% of patients reported
to be cured or improved in large FDA approved RCT4
≥80% success rates reported
when Bulkamid is used as a first-line treatment option1-3
The reported success rates of women treated with Bulkamid in 3 separate studies where Bulkamid was used as a
primary procedure1-3
Durable over time
Bulkamid has shown to maintain its efficacy at 1, 2, 5 and 7 years1,3-5
Maintained improvement in quality of life1
A graph showing ICIQ and VAS scores to 5 years following treatment with Bulkamid (n=256)
An excellent safety profile
An extremely low peri and postoperative complication rate in studies up to 7 years.
Author Toozs-Hobson5 Sokol4 Pai1 Lobodash3 Andrews2 Zivanovic6 Mohr7
Year of publication 2012 2014 2015 2015 2015 2016 2017
Number of patients 135 229 256 354 38 60 154
Procedure-related serious adverse events 0 (0%) 1 (0.4%)* 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Acute urinary retention 2 (1.4%) 13 (5.7%) 1 (0.4%) 0 (0%) 0 (0%) 0 (0%) 3 (1.9%)
Acute urinary infection 0 (0%) 8 (3.5%) 4 (1.6%) 6 (1.7%) 1 (2.6%) 2 (3.6%) 12 (7.8%)
Follow up period 24 months 12 months 5 years 7 years 6 months 12 months 3 months
Author
Year of publication
Number of patients
Procedure-related serious adverse events
Acute urinary retention
Acute urinary infection
Follow up period
* Transient haematuria
The importance of patient choice
Patients want an experience that includes engagement in shared decision making 9,10.
Patient choice and involvement in decision making are becoming more important in healthcare.
did not expect a complete cure of all bladder symptoms following a SUI treatment 2
expressed a preference for minor procedures with low risk of complications and are prepared to accept a lower success rate2
would like to be told about the risks associated with each treatment option1
would like to be told how treatment options may impact their quality of life1
“Patient decision aids support conversations and help patients make informed choices”
United Kingdom's National Institute for Health and Care Excellence (NICE)
Learn more

If you feel Bulkamid may be an option for your patients, or if you want to find out more, take a look at the following links.